Results 241 to 250 of about 39,918 (251)

Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease

Circulation, 2015
Alvaro Aa Avezum, Renato Delascio Lopes, Fernando Lanas   +2 more
exaly  

Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial

Lancet, The, 2012
Renato Delascio Lopes, Sana M Al-Khatib, M Cecilia Bahit   +2 more
exaly  

Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review

Clinical Pharmacokinetics, 2019
Wonkyung Byon, Samira Garonzik
exaly  

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

New England Journal of Medicine, 2019
Marc Carrier, Ranjeeta Mallick, Vicky Tagalakis   +2 more
exaly  

Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial

European Heart Journal, 2012
Stefan H Hohnloser, Ziad Hijazi, John H Alexander   +2 more
exaly  

Apixaban for Extended Treatment of Venous Thromboembolism

New England Journal of Medicine, 2013
Giancarlo Agnelli, Alexander T Cohen, Alexander S Gallus   +2 more
exaly  

Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation

Circulation, 2013
Renato Delascio Lopes, John H Alexander, Raffaele De Caterina   +2 more
exaly  

Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) Versus Warfarin in Patients With Atrial Fibrillation

American Journal of Cardiology, 2012
Sonia M Grandi, Kristian B Filion
exaly  

Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial

Lancet Neurology, The, 2012
John W. Eikelboom, Stuart J Connolly, Martin O'Donnell   +2 more
exaly  

Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial

American Heart Journal, 2017
Renato Delascio Lopes, Stuart J Connolly, Christopher B Granger   +2 more
exaly